Bluebird bio Inc

Bluebird bio — Investor Day (June 2017)

35 slides from Bluebird bio's investor day presentation, Jun 5, 2017

  1. Slide 1: bb2121 Investor & Analyst Event

    bb2121 Investor & Analyst Event June 5, 2017 NASDAQ: BLUE Exhibit 99.1

  2. Slide 2: Forward Looking Statements

    These slides and the accompanying oral presentation contain forward-looking statements and information relating to bluebird bio, its product candidate bb2121 and oncology research and development plans. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “belie

  3. Slide 3: Agenda

    Agenda Introduction bluebird Oncology Franchise CRB-401 Study Design and Clinical Overview CRB-401 Data Closing Q&A Manisha Pai, Nick Leschly Philip Gregory, D.Phil. M. Travis Quigley Jesus Berdeja, M.D. David Davidson, M.D. bluebird bio management Jesus Berdeja, M.D., principal investigator Michael

  4. Slide 4: Welcome

    Welcome Nick Leschly, chief bluebird

  5. Slide 5: Our Vision: Make Hope a Reality

    Our Vision: Make Hope a Reality TRUE BLUE BLUE MOJO OUR PATIENTS OUR PEOPLE

  6. Slide 6: Advancing Multiple Programs in Parallel

    Advancing Multiple Programs in Parallel MM TDT SCD CALD

  7. Slide 7: Our Strategic Intent

    Our Strategic Intent Severe Genetic Diseases Hematopoietic Stem Cells (HSCs) Immunotherapy T Cells Late Stage (LentiGlobin, Lenti-D) Big Near Term Opportunities (SCD, Multiple Myeloma) Best Team (300+) Great Partners Truly Integrated Platform Transformative Product Focus “Tetris” R&D (Anti-Pure Play

  8. Slide 8: bluebird Oncology Franchise

    bluebird Oncology Franchise Philip Gregory, D.Phil., chief scientific officer

  9. Slide 9: Pipeline

    CNS Diseases Pipeline Lenti-D™ Drug Product Yet Rare Hemoglobinopathies Lentictobin’ (Phase 3) Worldwide Drug Product ee bb2121 Celgene bb21217 Celgene Oncology HPV-16 E6 TCR Kite Pharma Viromed Target fem eres Medigene Targets Worldwide Research Early Pipeline Undisclosed + Gene Editing Worldwide C

  10. Slide 10: Good is Never Good Enough for Patients: bluebird Toolbox Strategy

    Good is Never Good Enough for Patients: bluebird Toolbox Strategy BCMA (bb2121) LentiGlobin v1.0 Transduction Durability BCMA & PI3Ki (bb21217) LentiGlobin & Enhancers v2.0 Novel areas; autoimmune In vivo gene editing Optimized severe genetic disease products New & enhanced oncology products vFuture

  11. Slide 11: Building a Translational Oncology Products Company

    Building a Translational Oncology Products Company: The Right Approach for the Right Targets Targets Tools Partnerships Immuno-Oncology R&D Engine Oncology Pipeline Access to targets: both CARs and TCRs Optimization: gene editing; manufacturing enhancements; on/off switches; product and technology c

  12. Slide 12: Tumor Specific Antigens e.g. Intracellular Targets

    Tumor Specific Antigens e.g. Intracellular Targets TCR technology provides T cell redirection to intracellular antigens not addressable by CARs Medigene partnership provides bluebird access to TCR therapeutic candidates against four targets Targets Personalized cancer treatment with TCRs Rapid, effi

  13. Slide 13: Building on the T Cell Chassis with Manufacturing Improvements and Genome Editing

    Example 1: bb21217 – making younger T cells Example 2: megaTALs – driving site specific CAR insertion Tools Building on the T Cell Chassis with Manufacturing Improvements and Genome Editing

  14. Slide 14: Building a Translational Oncology Products Company

    Building a Translational Oncology Products Company: The Right Approach for the Right Targets Access to targets: both CARs and TCRs Optimization: gene editing; manufacturing enhancements; on/off switches; product and technology combinations Internal focus on bluebird strengths coupled with academic a

  15. Slide 15: CRB-401 Study Design and Clinical Overview

    CRB-401 Study Design and Clinical Overview M. Travis Quigley BCMA program leader & senior director, clinical development

  16. Slide 16: Despite Progress in Multiple Myeloma, There Remains a Need for New Therapies

    Despite Progress in Multiple Myeloma, There Remains a Need for New Therapies Kenneth C. Anderson Clin Cancer Res 2016;22:5419-5427 “Despite the availability of these classes of drugs for the treatment of MM, a recent analysis of patients with relapsed and refractory MM (RRMM) who were double refract

  17. Slide 17: Current U.S. Standard of Care in 3rd/4th Line Multiple Myeloma

    Current U.S. Standard of Care in 3rd/4th Line Multiple Myeloma Current U.S. Standards of Care Pomalyst and dex. (Pomalyst Product Monograph) Daratumamab (Lancet 2016, Lonial, S) N 452 106 Inclusion Criteria ≥2 prior therapies (including REVLIMID and bortezomib) Relapsed and refractory multiple myelo

  18. Slide 18: BCMA – A Promising Target in Multiple Myeloma

    BCMA – A Promising Target in Multiple Myeloma Multiple myeloma cells expressing BCMA (brown color = BCMA protein) BCMA is member of the TNF receptor superfamily expressed nearly universally on multiple myeloma cells with expression largely restricted to plasma cells and some mature B cells Initial p

  19. Slide 19: Introduction to bb2121

    Introduction to bb2121 bb2121 is a second-generation CAR construct targeting BCMA, consisting of autologous T cells transduced with a lentiviral vector encoding a novel CAR incorporating an anti-BCMA scFv, a 4-1BB costimulatory motif to promote proliferation and persistence, and a CD3-zeta T cell ac

  20. Slide 20: CRB-401 Phase 1 Study in Relapsed / Refractory Multiple Myeloma

    CRB-401 Phase 1 Study in Relapsed / Refractory Multiple Myeloma Objectives: Determine preliminary safety and efficacy and recommended phase 2 dose N = 50 patients, standard 3 + 3 dose escalation + expansion cohort Eligibility: Relapsed / refractory MM with ≥ 3 prior lines of therapy (including PI an

  21. Slide 21: CRB-401 Data

    CRB-401 Data Jesus Berdeja, M.D. Sarah Cannon Research Institute & Tennessee Oncology

  22. Slide 22: First-in-Human Multicenter Study of bb2121 anti-BCMA CAR T Cell Therapy: Updated Results

    First-in-Human Multicenter Study of bb2121 anti-BCMA CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma: Updated Results Jesus G. Berdeja, MD1, Yi Lin, MD, PhD2, Noopur Raje, MD3, Nikhil Munshi, MD4, David Siegel, MD, PhD5, Michaela Liedtke, MD6, Sundar Jagannath, MD7, Marcela Maus, MD, PhD

  23. Slide 23: CRB-401 Open-label Phase 1 Clinical Study of bb2121

    CRB-401 Open-label Phase 1 Clinical Study of bb2121 Study Status CRB-401 is a phase 1 dose-escalation and dose response study in relapsed / refractory MM Objectives: Determine preliminary safety and efficacy and recommended phase 2 dose 50 patients planned, standard 3 + 3 dose escalation followed by

  24. Slide 24: Baseline Demographics, Clinical Characteristics and Treatment History

    Baseline Demographics, Clinical Characteristics and Treatment History 21 patients have received bb2121 as of the data cut-off of May 4, 2017. Median follow-up is 15.4 weeks (range 1.4 to 54.4). 1 ECOG: Eastern Cooperative Oncology Group Performance Score 2 ISS: International Staging System 3 SCT: St

  25. Slide 25: bb2121 Generally Well Tolerated

    No dose-limiting toxicities (DLTs) observed as of data cut-off Cytopenias related to Cy/Flu lymphodepletion 1 unrelated death due to cardio pulmonary arrest in a patient with an extensive cardiac history, the event occurred over 4 months after bb2121 infusion. The patient had achieved a stringent CR

  26. Slide 26: Cytokine Release Syndrome Readily Manageable

    Cytokine Release Syndrome Readily Manageable 15/21 (71%) with cytokine release syndrome (CRS) 2 patients with Grade 3 CRS that resolved in 24 hours 4 patients received tocilizumab, 1 (Grade 2 CRS) with steroids CRS grade does not appear related to tumor burden CRS-related symptoms mostly Grade 1-2 N

  27. Slide 27: All Patients in Active Dose Cohorts Achieved an Objective Response

    All Patients in Active Dose Cohorts Achieved an Objective Response, Duration up to 54 Weeks * High tumor burden (>50% bone marrow involvement) Includes unscheduled assessments.

  28. Slide 28: Clinical Response: Time to Response and MRD

    Clinical Response: Time to Response and MRD Efficacy Parameter % (95% CI) ORR all doses 89% (65-99) ORR (> 50 x 106 CAR+ cells) 100% (78.2-100) ≥VGPR (> 50 x 106 CAR+ cells) 73% CR rate (> 50 x 106 CAR+ cells) 27% Median (range) Time to First Response (days) 31 (15-92) Time to Best Response (days) 5

  29. Slide 29: Tumor Response Kinetics

    Tumor Response Kinetics: Rapid Clearance of PET Uptake, sBCMA and sFLC; Slower Clearance of M-protein PET imaging Pt 8 dFLC (% change from baseline)* Serum M-protein (% change from baseline) Serum BCMA (% change from baseline)

  30. Slide 30: Persistence of CAR T Cells in Peripheral Blood

    Persistence of CAR T Cells in Peripheral Blood up to 24 Weeks

  31. Slide 31: Summary

    Summary bb2121 has induced durable and deepening responses in a heavily pre-treated population with relapsed/refractory multiple myeloma, including: 100% ORR, 73% VGPR or better, 27% CR (at doses > 50 x 106) MRD negative results in all evaluable patients (N=4) No disease progression in patients trea

  32. Slide 32: Closing

    Closing David Davidson, M.D., chief medical officer

  33. Slide 33: Key Takeaways

    Key Takeaways As of May 4 Data Cut-off No DLTs; toxicity readily manageable, CRS largely grade 1/2, two Grade 3 CRS resolved within 24 hours with tocilizumab Safety Profile Responses Durability 100% response rate in active dose cohorts (above 50x106) 27% complete response rate 73% VGPR or better All

  34. Slide 34: Q&A

    Q&A bluebirddio

  35. Slide 35: Q&A

    Q&A Nick Leschly, chief bluebird David Davidson, M.D., chief medical officer Philip Gregory, D.Phil., chief scientific officer M. Travis Quigley, BCMA program leader & senior director, clinical development Jesus Berdeja, M.D., Sarah Cannon Research Institute & Tennessee Oncology Michael Pehl, presid

bluebird bio — Investor Day (June 2017) on 6ix